2021/04/19 by Julien Edeline, Roch Houot, Aurélien Marabelle +1 · 1 voice · 1 citation
Biochemistry, Genetics and Molecular Biology · Engineering · Medicine · #CAR-T cell therapy research #Nanowire Synthesis and Applications #Virus-based gene therapy research
paper · pdf · doi:10.1186/s13045-021-01067-5
openalex publication_date 2021/04/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their development in solid tumors. Nonetheless, the use of such new drugs to treat solid tumors is not straightforward. So far, the results from early phase clinical trials are not as impressive as expected but many improvements are under way. In this review we present an overview of the clinical development of CAR-T cells and BiTEs targeting the main antigens expressed by solid tumors. We emphasize the most frequent hurdles encountered by either CAR-T cells or BiTEs, or both, and summarize the strategies that have been proposed to overcome these obstacles.